Intraperitoneal radioactive phosphate in early ovarian carcinoma: an analysis of complications
- PMID: 2022522
- DOI: 10.1016/0360-3016(91)90189-b
Intraperitoneal radioactive phosphate in early ovarian carcinoma: an analysis of complications
Abstract
Intraperitoneal radioactive chromic phosphate was administered to 69 patients with Stage I and II ovarian carcinoma who had undergone comprehensive surgical staging. Intestinal obstruction requiring surgical intervention occurred in four patients and was the most severe complication. Abdominal pain was the most common post-therapy complaint. Attention to time and technique of drug administration could minimize complications.
Similar articles
-
Intraperitoneal radioactive chromic phosphate (P32) in the treatment of ovarian cancer.J Med Assoc Ga. 1984 Jan;73(1):21-5. J Med Assoc Ga. 1984. PMID: 6707541 No abstract available.
-
Five and ten year estimated survival and disease-free rates after intraperitoneal chromic phosphate; stage I ovarian adenocarcinoma.Am J Clin Oncol. 1988 Oct;11(5):515-9. doi: 10.1097/00000421-198810000-00001. Am J Clin Oncol. 1988. PMID: 3177251
-
Radioactivity in breast milk after intraperitoneal chromic phosphate for the treatment of early ovarian cancer.Am J Obstet Gynecol. 1983 Dec 1;147(7):840-1. doi: 10.1016/0002-9378(83)90054-6. Am J Obstet Gynecol. 1983. PMID: 6650612 No abstract available.
-
Update on the role of radiotherapy in ovarian cancer.Semin Oncol. 1998 Jun;25(3):361-71. Semin Oncol. 1998. PMID: 9633849 Review. No abstract available.
-
[Intraperitoneal irradiation in limited epithelial neoplasms of the ovary. Review of the literature].Minerva Ginecol. 1985 Jul-Aug;37(7-8):407-13. Minerva Ginecol. 1985. PMID: 3906441 Review. Italian. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical